News
AXGN
--
0.00%
--
Axogen names finance chief Peter Mariani as EVP
Axogen (AXGN) promotes CFO Peter J. Mariani to executive vice president, in addition to his current finance chief role.Mariani has served as Axogen’s chief financial officer since 2016"This expanded role recognizes
Seekingalpha · 6h ago
BRIEF-AxoGen Promotes Peter J. Mariani To Executive Vice President And Chief Financial Officer
reuters.com · 7h ago
Axogen Promotes Peter J. Mariani to Executive Vice Pres and Chief Fincl Officer
Axogen Promotes Peter J. Mariani to Executive Vice Pres and Chief Fincl Officer
Dow Jones · 7h ago
Axogen, Inc. Promotes Peter J. Mariani to Executive Vice President and Chief Financial Officer
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the promotion of Peter J. Mariani to Executive Vice President and Chief Financial Officer.
GlobeNewswire · 7h ago
10-K: AXOGEN, INC.
(EDGAR Online via COMTEX) -- ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following information should...
Edgar Online - (EDG = 10Q, 10K) · 16h ago
Nerve Repair and Regeneration Market Top Manufacturers, Size, Business Scenario, Share, Growth, Insights, Industry Analysis, Trends and Forecasts Report 2027
Mar 01, 2021 (Market Insight Reports) -- The global Nerve Repair and Regeneration Market will be worth USD 11.62 Billion by 2027, according to a current...
Market Insight Reports · 20h ago
Nerve Repair Biomaterials Market Research Report by Type, by Product, by Application – Global Forecast to 2025 – Cumulative Impact of COVID-19
Feb 25, 2021 (Heraldkeepers) -- The Global Nerve Repair Biomaterials Market is expected to exceed more than US$ 750.0 Million by 2024 at a CAGR of 11% in the...
Heraldkeepers · 4d ago
The Daily Biotech Pulse: Bausch Calls Truce With Icahn, Pfizer's Brain Inflammation Vaccine Gets Priority Review, BriaCell IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 23)
Benzinga · 5d ago
Canaccord Genuity Sticks to Their Hold Rating for AxoGen (AXGN)
SmarterAnalyst · 5d ago
AxoGen (AXGN) Receives a Hold from Canaccord Genuity
In a report issued on February 22, Kyle Rose from Canaccord Genuity maintained a Hold rating on AxoGen (AXGN), with a price target of $21.00. The
SmarterAnalyst · 5d ago
Leerink Partners Believes AxoGen (AXGN) Won’t Stop Here
In a report released yesterday, Richard Newitter from Leerink Partners maintained a Buy rating on AxoGen (AXGN), with a price target of $27.00. The
SmarterAnalyst · 5d ago
Canaccord Genuity Remains a Hold on AxoGen (AXGN)
Canaccord Genuity analyst Kyle Rose maintained a Hold rating on AxoGen (AXGN) on February 22 and set a price target of $21.00. The company's shares closed
SmarterAnalyst · 5d ago
DJ Axogen Is Maintained at Hold by Canaccord Genuity
Dow Jones · 6d ago
DJ Axogen Price Target Raised to $21.00/Share From $20.00 by Canaccord Genuity
Dow Jones · 6d ago
The Daily Biotech Pulse: Aridis To Study Antibody Cocktail For Coronavirus Variants, Revance & Protalix Data Readouts
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 22)
Benzinga · 6d ago
--Analyst Actions: SVB Leerink Adjusts AxoGen's Price Target to $27 From $23, Keeps Outperform Rating
MT Newswires · 6d ago
DJ Axogen Price Target Raised to $27.00/Share From $23.00 by SVB Leerink
Dow Jones · 6d ago
DJ Axogen Is Maintained at Outperform by SVB Leerink
Dow Jones · 6d ago
DJ AxoGen, Inc. CEO Karen Zaderej on Q4 2020 Results -- Earnings Call Transcript >AXGN
Dow Jones · 6d ago
AxoGen (AXGN) Gets a Hold Rating from BTIG
BTIG analyst Ryan Zimmerman maintained a Hold rating on AxoGen (AXGN) yesterday. The company's shares closed last Monday at $21.19. According to
SmarterAnalyst · 02/23 01:15
Webull provides a variety of real-time AXGN stock news. You can receive the latest news about Axogen Inc. through multiple platforms. This information may help you make smarter investment decisions.
About AXGN
AxoGen, Inc. offers surgical solutions for peripheral nerve injuries. The Company provides products and education to improve surgical treatment algorithms for peripheral nerve injuries. Its portfolio of products includes Avance Nerve Graft, AxoGuard Nerve Connector, AxoGuard Nerve Protector and Avive Soft Tissue Membrane. Along with these core surgical products, the Company also offers the AxoTouch Two-Point Discriminator, and AcroVal Neurosensory and Motor Testing System. These evaluation and measurement tools assist healthcare professionals in detecting changes in sensation; assessing return of sensory, grip and pinch function; evaluating treatment interventions, and providing feedback to patients on nerve function. Its portfolio of products is available in the United States, Canada, the United Kingdom and several European and other countries. The Company's products are used by surgeons during surgical interventions to repair a range of nerve injuries throughout the body.